The company had not issued any dividends in recent years.
The performance of Dermata Therapeutics in the marketplace will significantly impact your decision to invest in its stock. Revenue growth, profitability, competitive positioning, management quality, and industry trends can influence Dermata Therapeutics'
stock prices. When investing in Dermata Therapeutics, there are several factors to consider and potential outcomes to expect. As a company performs well, its stock price may increase, allowing investors to benefit from price appreciation. However, Dermata Stock can experience significant price fluctuations due to market conditions, economic factors, industry trends, or company-specific news. This is why investing in stocks such as Dermata Therapeutics carries risks, including the potential for capital loss. Stock prices can decline, and investors may incur losses if they sell shares at a lower price than their initial investment.
Watch out for price decline
Please consider monitoring Dermata Therapeutics on a daily basis if you are holding a position in it. Dermata Therapeutics is trading at a penny-stock level, and the possibility of delisting is much higher compared to other stocks. However, just because the stock is trading under one dollar, does not mean it will be marked for deletion.
Most exchanges require public instruments, such as Dermata Therapeutics stock to be traded above the $1 level to remain listed. If Dermata Therapeutics stock price falls below $1 for 30 consecutive trading days, the exchange can delist it. Once the company reaches this point, they will be sent an initial price violation notice directly from an exchange.
How important is Dermata Therapeutics's Liquidity
Dermata Therapeutics
financial leverage refers to using borrowed capital as a funding source to finance Dermata Therapeutics ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Dermata Therapeutics financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Financial leverage can amplify the potential profits to Dermata Therapeutics' owners, but it also increases the potential losses and risk of financial distress, including bankruptcy, if the firm cannot cover its debt costs. The degree of Dermata Therapeutics' financial leverage can be measured in several ways, including by ratios such as the debt-to-equity ratio (total debt / total equity), equity multiplier (total assets / total equity), or the debt ratio (total debt / total assets). Please check the
breakdown between Dermata Therapeutics's total debt and its cash.
Dermata Therapeutics Gross Profit
Dermata Therapeutics Gross Profit growth is one of the most critical measures in evaluating the company. The Gross Profit growth rate is calculated simply by comparing Dermata Therapeutics previous period's values with its current period's values. Each time period you're measuring should be of equal lengths the increase or decrease, in a company's Gross Profit between two periods. Here we show Dermata Therapeutics Gross Profit growth over the last 10 years. Please check Dermata Therapeutics'
gross profit and other
fundamental indicators for more details.
Breaking it down
Roughly 100.0 percent of Dermata Therapeutics outstanding shares are held by regular investors with 0.0 (percent) owned by
insiders and only 0.0 % by
other corporate entities.
Ownership Breakdown
| Retail Investors | 100.0 |
| Insiders | 0.0 |
| Institutions | 0.0 |
Our take on today Dermata Therapeutics rise
Current potential upside is at 8.7. Dermata Therapeutics is displaying above-average volatility over the selected time horizon. Investors should scrutinize Dermata Therapeutics independently to ensure intended market timing strategies are aligned with expectations about Dermata Therapeutics volatility. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Dermata Therapeutics' stock risk against market volatility during both bullying and bearish trends. The higher level of volatility that comes with bear markets can directly impact Dermata Therapeutics' stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different stocks as prices fall.
Dermata Therapeutics Implied Volatility
Dermata Therapeutics' implied volatility exposes the market's sentiment of Dermata Therapeutics stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if Dermata Therapeutics' implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that Dermata Therapeutics stock will not fluctuate a lot when Dermata Therapeutics' options are near their expiration.
The Bottom Line
Whereas some companies within the biotechnology industry are still a little expensive, even after the recent corrections, Dermata Therapeutics may offer a potential longer-term growth to investors. With an impartial outlook on the current market volatility, it may be better to hold off any inventment activity and neither trade nor short any shares of Dermata Therapeutics at this time. The Dermata Therapeutics risk-reward trade off is not appealing enough to do any trading. Please use our equity advice module to run different scenarios to ensure your current risk level and investment horizon are fully reflective of your current investing preferences in regards to Dermata Therapeutics.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectEditorial Staff
Ellen Johnson is a Member of Macroaxis Editorial Board. Ellen covers public companies in North America, focusing primarily on valuation and volatility. Six years of experience in predictive investment analytics and risk management.
View Profile This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Ellen Johnson do not own shares of Dermata Therapeutics. Please refer to our
Terms of Use for any information regarding our disclosure principles.
Would you like to provide feedback on the content of this article?
You can get in touch with us directly or send us a quick note via email to
editors@macroaxis.com
